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Abstract We previously demonstrated that p38 MAPK is a
crucial mediator in the NF-UB-dependent gene activation induced
by TNF. Here, we have studied the role of several TNF receptor-
associated proteins and caspases in p38 MAPK activation by
TNF. The latter appears to be dependent on TRAF2, but
independent of FADD or caspases. Remarkably, p38 MAPK
activation by TNF proceeds independently of the TRAF2-
associated NF-UB-inducing kinase NIK, which is known to bind
and activate two recently identified IUB kinases. These results
demonstrate that two kinase pathways involved in NF-UB
regulation, viz. NIK and p38 MAPK-mediated, diverge at the
level of TRAF2.
z 1998 Federation of European Biochemical Societies.
Key words: Tumor necrosis factor receptor-associated factor
2; p38 mitogen-activated protein kinase; Nuclear factor UB
1. Introduction
Tumor necrosis factor (TNF) elicits its wide spectrum of
cellular responses by binding to two distinct receptors, p55
(TNFR1) and p75 (TNFR2), the former mediating most
TNF activities [1]. Recently, our understanding of the TNF-
induced signaling pathways leading to gene expression or to
apoptosis has considerably increased with the isolation and
characterization of several TNFR-associated molecules. Acti-
vation of TNFR1 results in recruitment of a TNFR-associ-
ated death domain (TRADD) protein, which directly interacts
with Fas-associated death domain (FADD) protein and
TNFR-associated factor (TRAF) 2 [2^4]. FADD signals to
apoptosis by binding to caspase-8, which is believed to acti-
vate a proteolytic cascade of caspases [5,6]. On the other
hand, TRAF2 signals to nuclear factor (NF) UB by binding
to NF-UB-inducing kinase (NIK), a mitogen-activated protein
kinase (MAPK) kinase kinase-related molecule that forms a
complex with IUB kinase (IKK) K and L [7^9]. The latter are
directly responsible for activation of NF-UB by phosphorylat-
ing the NF-UB inhibitory protein IUB (reviewed in [10]). In
addition, it was recently shown that TRAF2 also mediates the
TNF-induced activation of the stress-activated protein kinase
JNK [9,11]. However, in contrast to the TRAF2-mediated
activation of IKK, JNK activation via TRAF2 is independent
of NIK and does not seem to play any role in NF-UB-depend-
ent gene induction by TNF [9]. p38 MAPK is another stress-
activated protein kinase that is activated by TNF and stress
stimuli [12]. We recently demonstrated that p38 MAPK is a
crucial mediator in TNF-induced activation of NF-UB-de-
pendent gene expression [13]. Because of the di¡erential role
of JNK and p38 MAPK in NF-UB activation, and the role of
distinct MAPK kinases in their activation [12], we decided to
analyze the role of several well-de¢ned TNF receptor-associ-
ated signaling molecules in TNF-induced p38 MAPK activa-
tion.
Our results demonstrate that p38 MAPK is speci¢cally ac-
tivated by a TRAF2-dependent pathway, but which is totally
independent of the FADD- and caspase-mediated pathways.
Moreover, p38 MAPK activation was independent of
TRAF2-associated NIK, suggesting that at least two kinase
pathways involved in NF-UB regulation diverge at the level of
TRAF2.
2. Materials and methods
2.1. Cells and reagents
HEK 293T and HeLa H21 cells were cultured in DMEM, and
KYM cells were cultured in RPMI, each supplemented with 2 mM
L-glutamine, 10% FCS (or 5% FCS and 5% newborn calf serum for
HeLa H21), 106 U/l streptomycin, 100 mg/l penicillin and 0.4 mM
sodium pyruvate. HeLa H21 cells stably expressing CrmA have been
described previously [14]. SB 203580 was generously provided by Dr.
J.C. Lee (SmithKline Beecham, King of Prussia, PA) and was dis-
solved in DMSO. Glutathione-coupled Sepharose beads were ob-
tained from Pharmacia Biotech (Uppsala, Sweden). GST-ATF2(1^
96) was purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). A L-galactosidase assay kit originated from ICN Pharmaceuti-
cals (Costa Mesa, CA). z-VAD-fmk was from Enzyme Systems Prod-
ucts (Dublin, CA). DEVD-AMC and YVAD-AMC were from Pep-
tide Institute (Osaka, Japan).
2.2. Plasmids and antibodies
pBEG-GSTp38 was obtained from Dr. L.E. Zon (Harvard Medical
School, Boston, MA [15]). pRK5-TRAF2 and pRK5-TRAF2(98^501)
were a generous gift from Dr. D.V. Goeddel (Tularik, San Francisco,
CA [3]). pNFconluc, which carries a luciferase gene under the control
of a minimal promoter preceded by three NF-UB-binding sites, was a
gift from Dr. A. Israeºl (Institut Pasteur, Paris, France [16]).
pCDNA3-FADD, pCDNA3-FADD(80^205), pCDNA3-NIK and
pCDNA3-NIK(KK429^430AA) were described previously [4,7].
pUT651, a L-galactosidase expression plasmid, was obtained from
Eurogentec (Seraing, Belgium). Anti-glutathione S-transferase (GST)
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antiserum was purchased from Upstate Biotechnology (Lake Placid,
NY). Anti-p38 MAPK phospho-speci¢c antiserum was from New
England Biolabs (Beverly, MA).
2.3. Transient transfection and in vitro immunocomplex p38 MAPK
assay
106 HEK 293T cells were seeded in 85-mm Petri dishes. 20 h later
cells were transfected, using the calcium-phosphate precipitation
method, with 0.5 Wg pUT651, 0.5 Wg pNFconluc, 1 Wg pBEG-
GSTp38 and 6 Wg empty vector or a plasmid expressing a TNFR-
associated protein. 48 h later, cells were either left untreated or treated
with 5000 IU/ml TNF. Cell lysates were prepared and p38 MAPK
activity was analyzed by an in vitro immunocomplex kinase assay
with 1 Wg GST-ATF-2(1^96) as a substrate [17]. After 30 min incu-
bation at 30‡C, the kinase reaction was terminated by adding
5ULaemmli sample bu¡er. Phosphorylated proteins were resolved
by 10% SDS-PAGE, visualized by autoradiography and quantitated
by phosphor imaging analysis. NF-UB-dependent reporter gene ex-
pression was parallelly analyzed as described previously [13] and nor-
malized for L-galactosidase activity.
2.4. Caspase activity assay
106 KYM cells or HeLa H21 cells were seeded in 6-well plates and
treated with TNF for 5 h. Some samples were pretreated for 2 h with
10 WM SB 203580. Cells were washed twice with PBS and resuspended
in lysis bu¡er (25 mM Tris-phosphate pH 7.8, 2 mM DTT, 2 mM 1,2-
cyclohexanediaminetetraacetic acid, 10% glycerol and 1% Triton
X-100), supplemented with protease inhibitors (1 mM Pefabloc and
20 Wg/ml aprotinin). Lysates were centrifuged at 13 000Ug ; cleared
supernatants were collected for enzymatic assays. Aliquots (20 Wg) of
the lysates were incubated with 50 WM YVAD-AMC or DEVD-AMC
for 60 min in a caspase reaction bu¡er, comprising 10 mM HEPES/
NaOH pH 7.4, 220 mM mannitol, 68 mM sucrose, 2 mM NaCl, 2.5
mM KH2PO4, 0.5 mM EGTA, 2 mM MgCl2, 5 mM sodium pyru-
vate, 0.1 mM PMSF and 1 mM DTT. Protease activities were deter-
mined by spectro£uorometry (Cyto£uor; PerSeptive Biosystems,
Cambridge, MA), monitoring the release of 7-amino-4-methylcoumar-
in (AMC) at an excitation wavelength of 380 nm and an emission
wavelength of 460 nm.
3. Results
3.1. TNF-induced p38 MAPK activation is mediated by
TRAF2 but not by FADD or NIK
To investigate the role of speci¢c TNFR-associated proteins
in TNF-induced p38 MAPK activation, HEK 293T cells were
cotransfected with pBEG-GSTp38 encoding GST-tagged hu-
man p38 MAPK [15], and a mammalian expression plasmid
encoding either TRAF2, NIK, FADD or dominant-negative
acting mutants of these molecules, viz. TRAF2(98^501),
FADD(80^205) or NIK(KK429^430AA), respectively [3,4,7].
48 h after transfection, GST-p38 was recovered using gluta-
thione-coupled Sepharose beads, after which p38 MAPK ac-
tivity was analyzed using a solid-phase kinase assay in which
GST-ATF2(1^96) was used as a substrate. In the case of
transfection with dominant-negative mutants, cells were
treated for 15 min with 5000 IU/ml TNF before cell lysis.
FADD overexpression had no e¡ect on p38 MAPK, while
the latter was strongly activated by TRAF2 overexpression
(Fig. 1A). Remarkably, the TRAF2-associated protein NIK
was unable to activate p38 MAPK. In line with the above
results, p38 MAPK activation by TNF was speci¢cally inhib-
ited by overexpression of a TRAF2 dominant-negative mu-
tant, while a dominant-negative mutant of FADD or NIK
had no e¡ect. Similar results were obtained when p38
MAPK activation was scored by measuring p38 MAPK phos-
phorylation with p38 MAPK phospho-speci¢c antibodies
(data not shown). These results show that TNF activates
p38 MAPK by a TRAF2-dependent, but NIK-independent
pathway. We also performed parallel experiments in which
an NF-UB-responsive luciferase reporter gene was cotrans-
fected to verify the e¡ect of the expressed TNFR-associated
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Fig. 1. E¡ect of overexpression of wild-type and dominant-negative mutants of TNFR-associated proteins on p38 MAPK and NF-UB activity.
HEK 293T cells were transiently cotransfected with pBEG-GSTp38, pUT651, pNFconluc, and a plasmid expressing a TNFR-associated protein
or an empty vector. 48 h after transfection, cells were either untreated or treated for 15 min (A) or 6 h (B) with 5000 IU/ml TNF before har-
vest, and analyzed for p38 MAPK activity on GST-ATF2 (A), or for NF-UB-dependent expression of a luciferase reporter gene (B). Results
obtained for TNF-treated samples are shown in black bars. Equal expression of GST-p38 was veri¢ed by immunoblot analysis with anti-GST
antiserum. Luciferase activities were normalized on the basis of L-galactosidase expression. Results shown are representative of three independ-
ent experiments. S.D. on luciferase expression was 6 10%.
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proteins on TNF-induced NF-UB activation. As expected,
overexpression of either TRAF2 or NIK led to NF-UB acti-
vation, whereas TRAF2(98^501) or NIK(KK429^430AA)
each blocked NF-UB activation by TNF (Fig. 1B). In conclu-
sion, our results point to a bifurcation of NIK- and p38
MAPK-mediated pathways leading to NF-UB activation at
the level of TRAF2.
3.2. Caspase inhibitors have no e¡ect on TNF-induced p38
MAPK activation
Caspases play an important role in TNF- and Fas-mediated
apoptosis. Recently, it was reported that Fas-activated cas-
pases act both upstream and downstream of the p38 MAPK
kinase MKK-6 [18], suggesting that p38 MAPK and caspases
function along the same pathway. Our ¢nding that p38
MAPK activation by TNF is FADD-independent suggests
that at least caspases triggered by the FADD/caspase-8 path-
way are not involved in p38 MAPK activation. In order to
clarify the possible regulatory relationship between p38
MAPK and caspases during TNF signalization, we analyzed
p38 MAPK activation by TNF in HeLa cells stably expressing
the viral caspase inhibitor CrmA, or which had been pre-
treated for 2 h with 10 WM of the caspase inhibitor peptide
z-VAD-fmk. It has previously been shown that CrmA expres-
sion or pretreatment with z-VAD-fmk protects these cells
against TNF-induced apoptosis [14]. Cells were lysed at di¡er-
ent times of TNF treatment, and p38 MAPK activation was
measured by analyzing p38 MAPK phosphorylation with
phospho-speci¢c antibodies on a Western blot (Fig. 2). p38
MAPK was maximally activated 15 min after TNF stimula-
tion. However, neither CrmA expression nor z-VAD-fmk
pretreatment had any e¡ect on p38 MAPK phosphoryla-
tion (only data for z-VAD-fmk-treated cells are shown),
although the cells were completely protected against TNF-
induced apoptosis (data not shown). Similar p38 MAPK
data were obtained in L929 cells. These results demonstrate
that TNF-induced activation of p38 MAPK is caspase-inde-
pendent.
3.3. TNF-induced caspase activation is p38 MAPK-independent
To investigate whether caspases might act downstream of
p38 MAPK, we studied the e¡ect of the p38 MAPK-speci¢c
inhibitor SB 203580 on TNF-induced activation of caspases.
HeLa H21 and KYM cells were treated for 2 h with 10 WM
SB 203580 before TNF treatment. This concentration has
previously been shown to inhibit completely TNF-induced
p38 MAPK activity and activation of an NF-UB-responsive
reporter gene [13]. HeLa H21 cells were sensitized to TNF by
treatment with cycloheximide as described previously [14].
After treatment with TNF for 5 h, the caspase activity in
cell lysates was measured on the £uorogenic peptide substrates
DEVD-AMC or YVAD-AMC, which are speci¢cally cleaved
by caspase-3 and caspase-1 family proteases, respectively [19].
In both cell lines, TNF treatment resulted in a signi¢cant
increase in caspase-3-like activity on DEVD-AMC, while no
activity could be detected on YVAD-AMC. However, pre-
treatment with SB 203580 had no e¡ect on TNF-induced cas-
pase activity (Fig. 3; only data for KYM cells are shown).
These results further demonstrate that caspases and p38
MAPK act along totally independent TNF-signaling path-
ways.
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Fig. 3. SB 203580 does not a¡ect TNF-induced caspase activity.
KYM cells were either untreated or treated for 2 h with 10 WM SB
203580 before stimulation with 2000 IU/ml TNF for 5 h. Cells were
harvested, and 20 Wg of total cellular protein was analyzed for pro-
teolytic activity on DEVD-AMC and YVAD-AMC. Data are ex-
pressed as an increase in £uorescence (F) as a function of time (vF/
min).
Fig. 4. Model proposed for TNFR1-initiated signaling pathways
leading to p38 MAPK and NF-UB activation, showing a bifurcation
at the level of TRADD and TRAF2.
Fig. 2. Inhibition of caspases has no e¡ect on TNF-induced activa-
tion of p38 MAPK. HeLa H21 cells were either untreated or treated
for 2 h with 10 WM z-VAD-fmk before stimulation with 2000 IU/ml
TNF. Cells were harvested, and 50 Wg of total cellular protein was
analyzed by SDS-PAGE and immunoblot analysis with p38 MAPK
phospho-speci¢c antibodies.
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4. Discussion
We have characterized the role of several TNF receptor-
associated proteins in TNF-induced activation of p38
MAPK and conclude that there is a bifurcation of the TNF
signal leading to p38 MAPK at the level of both TRADD and
TRAF2 (Fig. 4). TRAF2 has been implicated in TNF-induced
NF-UB activation by interacting with the MAPK kinase kin-
ase related protein NIK, which is part of an IKK complex
[10]. Our ¢nding that TRAF2 mediates p38 MAPK activation
by TNF, as well as the fact that p38 MAPK plays a crucial
role in TNF-induced activation of an NF-UB-dependent re-
porter gene [13], could suggest that NF-UB activation was
mediated by a signaling pathway consisting of TRAF2-
NIK-p38 MAPK. However, whereas TRAF2 is involved in
TNF-induced activation of both p38 MAPK and NF-UB,
we could not obtain any evidence for a role of NIK in p38
MAPK activation by TNF. This suggests the existence of two
di¡erent signals leading to NF-UB-dependent transcription,
the ¢rst being NIK-mediated and the second p38 MAPK-
mediated; these pathways would diverge at the level of
TRAF2. Similar to p38 MAPK, also activation of JNK has
recently been shown to be fully dependent on TRAF2
[9,11,20]. Divergence of pathways leading to p38 MAPK
and to JNK is likely to occur after TRAF2, presumably at
the level of MAPK kinases, such as MKK-3/6 and MKK-4/7,
respectively. The observation that p38 MAPK and JNK have
partially di¡erent substrate speci¢cities might explain the spe-
ci¢c role of p38 MAPK in NF-UB activation [12]. While this
article was in preparation, it was reported that TNF still ac-
tivates NF-UB in TRAF2-de¢cient cells, suggesting the exist-
ence of redundancy within the TRAF family or the role of
other pathways [20].
What might be the functional role of the p38 MAPK and
NIK pathways diverging at TRAF2? NIK was recently found
to associate with and to activate IKK-K and -L, which directly
phosphorylate the NF-UB inhibitory protein IUB. These mod-
i¢cations lead to the targeted degradation of IUB-K and -L via
the ubiquitin-proteasome pathway and subsequent transloca-
tion of NF-UB into the nucleus. In contrast, p38 MAPK se-
lectively modulates the transactivation potential of NF-UB
without interfering with IUB phosphorylation and NF-UB
translocation [13,17]. This is further suggested by the ¢nding
that the speci¢c p38 MAPK inhibitor SB 203580 also inhibits
the transactivation potential of the p65 NF-UB subunit in a
mammalian one-hybrid assay [21]. TNF-induced phosphoryl-
ation of p65 is apparently not a¡ected by SB 203580 [2],
suggesting that the p65 subunit is not a direct substrate of
p38 MAPK. Alternatively, p38 MAPK might phosphorylate
and activate other factors, including AP-1, p300/CBP, SRF,
ATF-2, steroid receptors and TFII-D, which physically and
functionally interact with NF-UB, and thus might cooperate in
directly activating NF-UB by a TRAF2/NIK-dependent path-
way.
Our observation that a FADD dominant-negative acting
mutant and several caspase inhibitors have no e¡ect on p38
MAPK activation by TNF, as well as the p38 MAPK-inde-
pendent activation of caspases, also clearly demonstrates that
p38 MAPK and caspases act along totally independent TNF-
activated pathways. This seems to be di¡erent from Fas-medi-
ated signaling, in which caspases act both upstream and
downstream of p38 MAPK [18]. The signaling role of p38
MAPK activation after Fas stimulation might therefore be
rather di¡erent from its role in TNF signaling.
In conclusion, we have demonstrated that the TNF-signal-
ing pathway leading to p38 MAPK activation and NF-UB-
dependent gene activation is totally independent of caspases,
and diverges not only at the level of TRADD, but also at the
level of TRAF2. Experiments to identify the mediator linking
TRAF2 to p38 MAPK are currently in progress.
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